Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management
Background Depression is a prodromic and a frequent non-motor symptom of Parkinson’s disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions. Methods A Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson’s disease. Results and conclusion Experts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients’ characteristics..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Neurological sciences - 44(2023), 9 vom: 27. Apr., Seite 3123-3131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stocchi, Fabrizio [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Delphi Consensus |
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s10072-023-06740-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144937605 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144937605 | ||
| 003 | DE-627 | ||
| 005 | 20240118101842.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-023-06740-w |2 doi | |
| 035 | |a (DE-627)OLC2144937605 | ||
| 035 | |a (DE-He213)s10072-023-06740-w-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90$jNeurologie |2 bkl | ||
| 100 | 1 | |a Stocchi, Fabrizio |e verfasserin |0 (orcid)0000-0002-5763-0033 |4 aut | |
| 245 | 1 | 0 | |a Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Depression is a prodromic and a frequent non-motor symptom of Parkinson’s disease, associated to reduced quality of life and poor outcomes. The diagnosis of depression in parkinsonian patients represents a challenge due to the overlapping of symptoms typical of the two conditions. Methods A Delphi panel survey was performed to reach a consensus amongst different Italian specialists on four main topics: the neuropathological correlates of depression, main clinical aspects, diagnosis, and management of depression in Parkinson’s disease. Results and conclusion Experts have recognized that depression is an established risk factor of PD and that its anatomic substrate is related to the neuropathological abnormalities typical of the disease. Multimodal and SSRI antidepressant have been confirmed as a valid therapeutic option in the treatment of depression in PD. Tolerability, safety profile, and potential efficacy on broad spectrum of symptoms of depression including cognitive symptoms and anhedonia should be considered when selecting an antidepressant and the choice should be tailored on the patients’ characteristics. | ||
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Delphi Consensus | |
| 650 | 4 | |a SSRI | |
| 650 | 4 | |a Multimodal antidepressants | |
| 700 | 1 | |a Barone, Paolo |4 aut | |
| 700 | 1 | |a Bellelli, Giuseppe |4 aut | |
| 700 | 1 | |a Fagiolini, Andrea |4 aut | |
| 700 | 1 | |a Ferini Strambi, Luigi |4 aut | |
| 700 | 1 | |a Sorbi, Sandro |4 aut | |
| 700 | 1 | |a Padovani, Alessandro |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Springer International Publishing, 1999 |g 44(2023), 9 vom: 27. Apr., Seite 3123-3131 |w (DE-627)320571521 |w (DE-600)2016546-8 |x 1590-1874 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:9 |g day:27 |g month:04 |g pages:3123-3131 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10072-023-06740-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PSY | ||
| 936 | b | k | |a 44.90$jNeurologie |q VZ |0 106409980 |0 (DE-625)106409980 |
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 9 |b 27 |c 04 |h 3123-3131 | ||